Drug Trial Radar · NCT02612662
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 24, 2015
Primary completion
Nov 4, 2017
Study completion Oct 27, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Basic science
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses
Conditions
- Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD4076Drug
Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
PlaceboDrug
Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety and tolerability of AZD4076 by assessment of blood pressureTime frame: From screening until 16 weeks postdose, up to 5 months
- The safety and tolerability of AZD4076 by assessment of pulseTime frame: From screening until 16 weeks postdose, up to 5 months
- The safety and tolerability of AZD4076 by assessment of oral temperatureTime frame: From screening until 72 hours postdose
- The safety and tolerability of AZD4076 by assessment of electrocardiogram readingsTime frame: From screening until 16 weeks postdose, up to 5 months
- The safety and tolerability of AZD4076 by assessment of digital electrocardiogram readingsTime frame: From predose until 72 hours postdose
- The safety and tolerability of AZD4076 by assessment of cardiac telemetryTime frame: On Day -1 and predose until 72 hours postdose
- The safety and tolerability of AZD4076 by assessment of physical examinationTime frame: From screening until 16 weeks postdose, up to 5 months
- The safety and tolerability of AZD4076 by assessing hematologyTime frame: From screening until 16 weeks postdose, up to 5 months
- The safety and tolerability of AZD4076 by assessing the injection siteTime frame: Postdose until 72 hours
- The safety and tolerability of AZD4076 by assessming the number of adverse eventsTime frame: From screening until 16 weeks postdose, up to 5 months
- The safety and tolerability of AZD4076 by assessing clinical chemistryTime frame: From screening until 16 weeks postdose, up to 5 months
- The safety and tolerability of AZD4076 by assessing urinalysisTime frame: From screening until 16 weeks postdose, up to 5 months
- The safety and tolerability of AZD4076 by assessing the number of participants with adverse eventsTime frame: From screening until 16 weeks postdose, up to 5 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Brooklyn, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.